[go: up one dir, main page]

PE20110773A1 - Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion - Google Patents

Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion

Info

Publication number
PE20110773A1
PE20110773A1 PE2011001127A PE2011001127A PE20110773A1 PE 20110773 A1 PE20110773 A1 PE 20110773A1 PE 2011001127 A PE2011001127 A PE 2011001127A PE 2011001127 A PE2011001127 A PE 2011001127A PE 20110773 A1 PE20110773 A1 PE 20110773A1
Authority
PE
Peru
Prior art keywords
piperidinone
decan
ona
aza
oxa
Prior art date
Application number
PE2011001127A
Other languages
English (en)
Inventor
Zhongli Gao
Ryan Hartung
David Stefany
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20110773A1 publication Critical patent/PE20110773A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TETRAHIDROPIRAN ESPIRO PIRROLIDINONA Y PIPERIDINONA SUSTITUIDOS DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C4), CF3 O ALCOXI(C1-C4)-ALQUILO(C1-C4); R2 ES H, HALOGENO, ALQUILO(C1-C4) O CF3; m, n Y p SON CADA UNO 1 O 2. SON COMPUESTOS PREFERIDOS: 2-[4-((2S,3'S)-2-METIL-[1,3']BIPIRROLIDINIL-1'-IL)-FENIL]-8-OXA-2-AZA-ESPIRO[4.5]DECAN-1-ONA; 2-{2-METIL-4-[4-((S)-2-METIL-PIRROLIDIN-1-IL)-PIPERIDIN-1-IL]-FENIL}-8-OXA-2-AZA-ESPIRO[4.5]DECAN-1-ONA; 2-[2-FLUORO-4-(2-ISOPROPIL-[1,3']BIPIRROLIDINIL-1'-IL)-FENIL]-8-OXA-2-AZA-ESPIRO[4.5]DECAN-1-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE HISTAMINA H3 SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE PARKINSON, EPILEPSIA, INSOMNIO
PE2011001127A 2008-12-05 2009-12-04 Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion PE20110773A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12008708P 2008-12-05 2008-12-05
FR0955909 2009-08-28

Publications (1)

Publication Number Publication Date
PE20110773A1 true PE20110773A1 (es) 2011-10-26

Family

ID=41665099

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001127A PE20110773A1 (es) 2008-12-05 2009-12-04 Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion

Country Status (27)

Country Link
US (2) US8217052B2 (es)
EP (1) EP2373659B1 (es)
JP (1) JP5410544B2 (es)
KR (1) KR101682889B1 (es)
CN (1) CN102239170B (es)
AR (1) AR074467A1 (es)
AU (1) AU2009322243B2 (es)
CA (1) CA2745715C (es)
CO (1) CO6390059A2 (es)
CR (1) CR20110289A (es)
DO (1) DOP2011000166A (es)
EC (1) ECSP11011109A (es)
ES (1) ES2507574T3 (es)
HN (1) HN2011001487A (es)
IL (1) IL213292A (es)
MA (1) MA32945B1 (es)
MX (1) MX2011004791A (es)
MY (1) MY150789A (es)
NZ (1) NZ593150A (es)
PA (1) PA8852301A1 (es)
PE (1) PE20110773A1 (es)
RU (1) RU2519778C2 (es)
TN (1) TN2011000223A1 (es)
TW (1) TWI441826B (es)
UA (1) UA104880C2 (es)
WO (1) WO2010065798A1 (es)
ZA (1) ZA201103261B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
JP5766278B2 (ja) 2010-05-11 2015-08-19 サノフイ 置換されたｎ−アルキルおよびｎ−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用
AR081383A1 (es) 2010-05-11 2012-08-29 Sanofi Aventis N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central.
JP2013526530A (ja) * 2010-05-11 2013-06-24 サノフイ 置換されたｎ−フェニルスピロラクタムビピロリジン、その製造及び治療上の使用
WO2011143150A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
TW201206910A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
JP5784110B2 (ja) 2010-05-11 2015-09-24 サノフイ 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
TW201202251A (en) 2010-05-11 2012-01-16 Sanofi Aventis Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256276A (en) * 1961-02-17 1966-06-14 Geschickter Fund Med Res Substituted spiroimides
US3258276A (en) 1964-04-06 1966-06-28 Charles E Murcott Utility chair
JP4563675B2 (ja) * 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
US6889262B1 (en) 2002-06-26 2005-05-03 Advanced Micro Devices, Inc. Direct transaction mode for peripheral devices
CA2504272A1 (en) * 2002-10-23 2004-05-06 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
CN1902177A (zh) * 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
US8008296B2 (en) * 2005-07-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
WO2007055418A1 (ja) * 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. アザ置換スピロ誘導体
AU2006326067A1 (en) 2005-12-16 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo [2 , 3-b] pyridine derivatives as H3 receptor modulators
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
EP2038256A1 (en) * 2006-05-23 2009-03-25 TransTech Pharma, Inc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament
EP2049473A2 (en) 2006-06-29 2009-04-22 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
WO2009039431A2 (en) 2007-09-21 2009-03-26 Neurogen Corporation Substituted aryl-fused spirocyclic amines
WO2009052063A1 (en) 2007-10-17 2009-04-23 Sanofi-Aventis Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
BRPI0818581A2 (pt) 2007-10-17 2015-07-21 Sanofi Aventis Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas
RU2477719C2 (ru) 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.

Also Published As

Publication number Publication date
RU2519778C2 (ru) 2014-06-20
JP5410544B2 (ja) 2014-02-05
EP2373659B1 (en) 2014-07-30
JP2012511011A (ja) 2012-05-17
CR20110289A (es) 2011-09-21
TN2011000223A1 (en) 2012-12-17
ES2507574T3 (es) 2014-10-15
EP2373659A1 (en) 2011-10-12
AU2009322243A1 (en) 2011-06-23
TWI441826B (zh) 2014-06-21
DOP2011000166A (es) 2011-10-31
US8217052B2 (en) 2012-07-10
CA2745715A1 (en) 2010-06-10
AU2009322243B2 (en) 2015-07-16
US8383814B2 (en) 2013-02-26
KR20110095911A (ko) 2011-08-25
PA8852301A1 (es) 2010-07-27
CN102239170A (zh) 2011-11-09
MA32945B1 (fr) 2012-01-02
ZA201103261B (en) 2012-01-25
TW201033219A (en) 2010-09-16
WO2010065798A1 (en) 2010-06-10
MY150789A (en) 2014-02-28
NZ593150A (en) 2012-10-26
RU2011127382A (ru) 2013-01-10
IL213292A (en) 2014-01-30
US20120238757A1 (en) 2012-09-20
MX2011004791A (es) 2011-05-30
AR074467A1 (es) 2011-01-19
UA104880C2 (uk) 2014-03-25
CA2745715C (en) 2014-01-28
HN2011001487A (es) 2013-12-02
ECSP11011109A (es) 2011-11-30
CN102239170B (zh) 2014-08-20
CO6390059A2 (es) 2012-02-29
IL213292A0 (en) 2011-07-31
KR101682889B1 (ko) 2016-12-06
US20110251225A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
PE20110773A1 (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion
PE20090248A1 (es) Moduladores de beta-amiloide
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
PE20110568A1 (es) Agentes terapeuticos 414
TW201144306A (en) Bicyclic heteroaryl analogues as GPR119 modulators
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
GB0517191D0 (en) Compounds
MX2014006210A (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20110136A1 (es) Compuestos organicos
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20120261A1 (es) Piperidina espiro pirrolidinona y piperidinonas sustitudos como moduladores de los receptores h3
TN2011000368A1 (en) Fused ring compound and use thereof

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed